Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Novel Therapies for the Treatment of Skin Diseases
share announcement

Novel Therapies for the Treatment of Skin Diseases

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (25 March 2024) | Viewed by 12279

Special Issue Editor

Dr. Lingli Yang

E-Mail Website
Guest Editor
Department of Pigmentation Research and Therapeutics, Graduate School of Medicine, Osaka Metropolitan University, Osaka 5450051, Japan
Interests: drug discovery; kinase inhibitors; proteinase inhibitors; natural products; bioactive natural compounds; herbal extracts; skin; skin color; skin microbiomes; skin diseases; hair; keratinocytes; melanocytes; fibroblasts; vitiligo; albinism; melasma; lentigo; halo nevus; hypopigmentation; gray hair; alopecia; skin fibrosis; wound healing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent decades, our understanding in the field of skin diseases has taken a major step forward on a molecular to clinical level. Despite these valuable developments, however, patients experiencing skin diseases such as vitiligo, melasma, lentigo, gray hair, alopecia, skin fibrosis, although treated, remain uncured; sometimes, these diseases are lifelong, and many unmet needs remain in this field, with more effective and safe therapies expected to be developed. Importantly, the pathogenesis and molecular basis of skin diseases are often not fully understood. To be able to fulfill these requirements, scientists and clinicians should better understand molecular pathogenesis and choose among existing therapies or even develop new ones.

The aim of this Special Issue is to describe innovative approaches for efficacious treatment of skin diseases including vitiligo, albinism, melasma, lentigo, halo nevus, hypopigmentation, gray hair, alopecia, skin fibrosis, and wound healing. Studies regarding the biological and molecular mechanisms of new compounds which may be used in the future in the therapy of skin disorders as well as clinical submissions with biomolecular experiments are welcomed.

Dr. Lingli Yang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pigmentation
  • vitiligo
  • albinism
  • melasma
  • lentigo
  • halo nevus
  • melanoma
  • gray hair
  • skin fibrosis
  • wound healing

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 5215 KiB  
Article
Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses
by Elena Campione, Antonia Rivieccio, Ruslana Gaeta Shumak, Gaetana Costanza, Terenzio Cosio, Sara Lambiase, Virginia Garofalo, Fabio Artosi, Flavia Lozzi, Claudia Freni, Alice Romeo, Emi Dika, Mattia Falconi and Luca Bianchi
Pharmaceuticals 2023, 16(12), 1686; https://doi.org/10.3390/ph16121686 - 4 Dec 2023
Cited by 6 | Viewed by 2015
Abstract
Background: Actinic keratosis is a common precancerous skin lesion that can progress into invasive squamous cell carcinomas. Many topical treatments for actinic keratoses often have poor tolerability and prolonged duration. Tirbanibulin is a novel synthetic drug with potent antitumor and antiproliferative activities. Methods: [...] Read more.
Background: Actinic keratosis is a common precancerous skin lesion that can progress into invasive squamous cell carcinomas. Many topical treatments for actinic keratoses often have poor tolerability and prolonged duration. Tirbanibulin is a novel synthetic drug with potent antitumor and antiproliferative activities. Methods: We conducted a single-center, prospective and observational study using tirbanibulin ointment on a 25 cm2 area for 5 consecutive days on 30 participants with AKs on the face or scalp. They were followed for at least 57 days to assess the safety profile and efficacy of the drug as well as treatment satisfaction. We evaluated six signs of local skin reaction (LSR): erythema, scaling, crusting, swelling, blisters/pustules, and erosions/ulcerations, grading the severity as mild, moderate, or severe. The effectiveness was evaluated both clinically and dermoscopically. The treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Results: On day 57, 70% of the patients showed a complete clinical and dermoscopic response. The highest scores obtained from the TSQM 1.4 were more evident in the convenience and side effects domains. Most LSRs, including erythema (83.3%), scaling (30%), and swelling (3.3%), occurred on day 8 but resolved spontaneously. Conclusion: Tirbanibulin is a viable therapeutic option with a short regimen treatment and good tolerability, which favors therapy adherence. Full article
(This article belongs to the Special Issue Novel Therapies for the Treatment of Skin Diseases)
►▼ Show Figures

Figure 1

15 pages, 8909 KiB  
Article
Gallic Acid Treats Hypertrophic Scar in Rabbit Ears via the TGF-β/Smad and TRPC3 Signaling Pathways
by Qiannan Li, Chunming Lyu, Daqin Chen, Wanling Cai, Fang Kou, Qiang Li, Hai Wei and Huimin Zhang
Pharmaceuticals 2023, 16(11), 1514; https://doi.org/10.3390/ph16111514 - 24 Oct 2023
Cited by 3 | Viewed by 1718
Abstract
Hypertrophic scars (HSs) develop due to excessive collagen deposition and abnormal fibroblast proliferation during wound healing, significantly impacting patient quality of life. Three dosages of GA ointments were administered to rabbit ear HS models to investigate the potential efficacy and mechanism of gallic [...] Read more.
Hypertrophic scars (HSs) develop due to excessive collagen deposition and abnormal fibroblast proliferation during wound healing, significantly impacting patient quality of life. Three dosages of GA ointments were administered to rabbit ear HS models to investigate the potential efficacy and mechanism of gallic acid (GA) on HS. Daily application of ointment was performed on the matrix group, the GA ointment groups, and the silicone gel group for 28 days. (No drug treatment was performed on the skin and model groups as a blank group and vehicle group, and silicone gel ointment was topically administered to the silicone gel group as a positive control group.) Scar specimens were collected for histopathology analysis, RNA sequencing analysis, real-time quantitative polymerase chain reaction, and Western blot analysis at the first, second, and fourth weeks after the treatment. Low-dose and medium-dose GA effectively suppressed HS formation and markedly decreased fibroblast infiltration levels and scar thickness. Moreover, decreased expression of TRPC3 mRNA and TGF-β1, p-Smad2/3, and Smad2/3 protein was observed in the low- and medium-dose GA groups and the silicone gel group. This study provides evidence for the efficacy of GA in treating HS and sheds light on its potential underlying pharmacological mechanisms. Full article
(This article belongs to the Special Issue Novel Therapies for the Treatment of Skin Diseases)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

26 pages, 1052 KiB  
Review
Melanin Biopolymers in Pharmacology and Medicine—Skin Pigmentation Disorders, Implications for Drug Action, Adverse Effects and Therapy
by Marta Karkoszka, Jakub Rok and Dorota Wrześniok
Pharmaceuticals 2024, 17(4), 521; https://doi.org/10.3390/ph17040521 - 18 Apr 2024
Cited by 8 | Viewed by 2278
Abstract
Melanins are biopolymeric pigments formed by a multi-step oxidation process of tyrosine in highly specialized cells called melanocytes. Melanin pigments are mainly found in the skin, iris, hair follicles, and inner ear. The photoprotective properties of melanin biopolymers have been linked to their [...] Read more.
Melanins are biopolymeric pigments formed by a multi-step oxidation process of tyrosine in highly specialized cells called melanocytes. Melanin pigments are mainly found in the skin, iris, hair follicles, and inner ear. The photoprotective properties of melanin biopolymers have been linked to their perinuclear localization to protect DNA, but their ability to scavenge metal ions and antioxidant properties has also been noted. Interactions between drugs and melanins are of clinical relevance. The formation of drug–melanin complexes can affect both the efficacy of pharmacotherapy and the occurrence of adverse effects such as phototoxic reactions and discoloration. Because the amount and type of melanin synthesized in the body is subject to multifactorial regulation—determined by both internal factors such as genetic predisposition, inflammation, and hormonal balance and external factors such as contact with allergens or exposure to UV radiation—different effects on the melanogenesis process can be observed. These factors can directly influence skin pigmentation disorders, resulting in hypopigmentation or hyperpigmentation of a genetic or acquired nature. In this review, we will present information on melanocyte biology, melanogenesis, and the multifactorial influence of melanin on pharmacological parameters during pharmacotherapy. In addition, the types of skin color disorders, with special emphasis on the process of their development, symptoms, and methods of treatment, are presented in this article. Full article
(This article belongs to the Special Issue Novel Therapies for the Treatment of Skin Diseases)
►▼ Show Figures

Figure 1

18 pages, 1356 KiB  
Review
Recent Advances in the Management of Rosacea through Natural Compounds
by Iulia Semenescu, Diana Similie, Zorita Diaconeasa and Corina Danciu
Pharmaceuticals 2024, 17(2), 212; https://doi.org/10.3390/ph17020212 - 6 Feb 2024
Cited by 1 | Viewed by 5613
Abstract
Rosacea is a chronic skin disorder that affects more than 5% of the world’s population, with the number increasing every year. Moreover, studies show that one-third of those suffering from rosacea report a degree of depression and are less compliant with treatment. Despite [...] Read more.
Rosacea is a chronic skin disorder that affects more than 5% of the world’s population, with the number increasing every year. Moreover, studies show that one-third of those suffering from rosacea report a degree of depression and are less compliant with treatment. Despite being the subject of prolonged studies, the pathogenesis of rosacea remains controversial and elusive. Since most medications used for the management of this pathology have side effects or simply do not yield the necessary results, many patients lose trust in the treatment and drop it altogether. Thus, dermato-cosmetic products with natural ingredients are gaining more and more notoriety in front of synthetic ones, due to the multiple benefits and the reduced number and intensity of side effects. This review is a comprehensive up-to-date report of studies that managed to prove the beneficial effects of different botanicals that may be useful in the short and long-term management of rosacea-affected skin. Based on recent preclinical and clinical studies, this review describes the mechanisms of action of a large array of phytochemicals responsible for alleviating the clinical symptomatology of the disease. This is useful in further aiding and better comprehending the way plant-based products may help in managing this complex condition, paving the way for research in this area of study. Full article
(This article belongs to the Special Issue Novel Therapies for the Treatment of Skin Diseases)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop